All In Biotech

Drug Trial Radar · NCT04272957

A Study of HMPL-306 in Patients With IDH1 and/or IDH2 Mutation of Relapsed/Refractory Myeloid Leukemia/Neoplasms

A Phase I, Open-Label, Multicenter Study to Assess the Safety, Pharmacokinetics and Efficacy of HMPL-306 in Patients of Relapsed/Refractory Myeloid Leukemia/Neoplasms With IDH1 and/or IDH2 Mutation

Last checked: Nov 19, 2026Latest source record: Jun 16, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

75

Planned (sponsor's estimate)

Start

May 14, 2020

Primary completion

Jun 30, 2021

Study completion Dec 30, 2022

Sponsor

Lead sponsor
Hutchison Medipharma LimitedIndustry
Sponsor type
Industry
First posted
Feb 17, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Phase I, multicenter study to evaluate the safety, pharmacokinetics, pharmacodynamics and efficacy of HMPL-306 in Patients of Relapsed/Refractory Myeloid Leukemia/Neoplasms with IDH1 and/or IDH2 Mutation.

Conditions

  • Acute Myeloid Leukemia

Interventions

  • HMPL-306Drug

    HMPL-306 administered continuously as a single agent starting at 25 mg orally every day in a 28-day cycle and dose escalation is planned up to 200mg. Subjects may continue treatment with HMPL-306 until disease progression, development of other unacceptable toxicity or hematopoietic stem cell transplant.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety and tolerability: Incidence of adverse eventsTime frame: Baseline up to the last patient has completed the 24 weeks of treatment
  2. Maximum tolerated dosage (MTD) and/or recommended phase 2 dosage (RP2D)Time frame: Baseline up to the last patient has completed the 24 weeks of treatment

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Peking University People's Hospital

    Beijing, Beijing Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.